Abstract: The present invention relates to orally administered liquid pharmaceutical compositions of eslicarbazepine. The liquid compositions are in the form of ready to use suspension and suspension powder for reconstitution. It also relates to the processes for the preparation of said liquid compositions. The present invention provides liquid compositions of eslicarbazepine with desired technical attributes such as release profile and pH. The prepared compositions are useful in patients having difficulties in swallowing tablets and provide physician with providing a more convenient and less cumbersome posology.

Abstract: Described herein are dental treatment compositions, more particularly, a dental varnish composition useful in effective fluoridation, enhancement of remineralization the tooth enamel, and hypersensitivity through occlusion of dentine tubule. The dental varnish composition includes a hydrogel system and at least one fluoride source, wherein the dental varnish is water soluble. The hydrogel system includes at least one polyphenol having at least one phenol group, at least one polymer, and a metal ion. Described herein are also methods of making dental varnish composition in a single step and one pot synthesis.

Abstract: The present invention discloses an extended release oral liquid pharmaceutical composition comprising eslicarbazepine or its pharmaceutically acceptable esters, salts, solvates, polymorphs, enantiomers or mixtures thereof in a pharmaceutically acceptable carrier. The extended release liquid compositions are in the form of ready-to-use liquid compositions or reconstituted liquid compositions. It also relates to processes for the preparation of said extended release liquid compositions. The prior art discloses immediate release oral liquid dosage form. The prepared novel test formulations exhibited desired pharmaceutical technical attributes.

Abstract: Systems and methods are provided for facilitating mobile commerce interactions between a customer and a merchant, whereby a customer, having initiated a mobile commerce transaction via a mobile device, arrives at a merchant location to complete the transaction. In some embodiments, an intermediate remote server is employed to facilitate communication between a third party app running on a customer mobile computing device, and an app-agnostic merchant computing device residing at a merchant location. In some embodiments, the relative signal strength of a local wireless transceiver associated with a customer mobile computing device is employed to determine the proximity of a customer relative to a merchant at a merchant's premises. This proximity information may be employed to display, on the merchant computing device, a list of customers that is prioritized according to relative proximity.

Abstract: The present invention discloses an extended release oral liquid pharmaceutical composition comprising eslicarbazepine or its pharmaceutically acceptable esters, salts, solvates, polymorphs, enantiomers or mixtures thereof in a pharmaceutically acceptable carrier. The extended release liquid compositions are in the form of ready-to-use liquid compositions or reconstituted liquid compositions. It also relates to processes for the preparation of said extended release liquid compositions. The prior art discloses immediate release oral liquid dosage form. The prepared novel test formulations exhibited desired pharmaceutical technical attributes.

Abstract: The present invention relates to orally administered liquid pharmaceutical compositions of eslicarbazepine. The liquid compositions are in the form of ready to use suspension and suspension powder for reconstitution. It also relates to the processes for the preparation of said liquid compositions. The present invention provides liquid compositions of eslicarbazepine with desired technical attributes such as release profile and pH. The prepared compositions are useful in patients having difficulties in swallowing tablets and provide physician with providing a more convenient and less cumbersome posology.

Abstract: The present invention relates to a stable ready to use and powder for oral suspension dosage forms of Lamotrigine and its pharmaceutically acceptable salts and process of preparing such compositions. The liquid and powder for oral suspension dosage forms of Lamotrigine have been previously known only as extemporaneous preparations. Present invention relates to manufacture of liquid and powder for oral suspension dosage forms of Lamotrigine having improved physico-chemical properties with desired technical attributes. The prepared dosage forms are useful in patients having difficulties in swallowing tablets and provide physician with more options for dose titration.

Abstract: Described herein are dental treatment compositions, more particularly, a dental varnish composition useful in effective fluoridation, enhancement of remineralization the tooth enamel, and hypersensitivity through occlusion of dentine tubule. The dental varnish composition includes a hydrogel system and at least one fluoride source, wherein the dental varnish is water soluble. The hydrogel system includes at least one polyphenol having at least one phenol group, at least one polymer, and a metal ion. Described herein are also methods of making such dental varnish composition.

Abstract: Described herein are dental compositions, more particularly water soluble dental varnish composition useful for effective fluoridation, in situ biomimetic remineralization and improved adhesion to enamel. The dental composition includes a hydrogel-forming polymer having cohesive properties to itself and adhesive properties to a dental enamel. The hydrogel forming polymer includes a water-soluble polymer and an adhesion promotor chemically and/or physically conjugated to the water-soluble polymer. The embodiments also provide methods of forming a hydrogel forming polymer and use of hydrogel forming polymer to prepare such dental composition.

Abstract: Described herein are dental compositions, more particularly water soluble dental varnish composition useful for effective fluoridation, in situ biomimetic remineralization and improved adhesion to enamel. The dental composition includes a hydrogel-forming polymer having cohesive properties to itself and adhesive properties to a dental enamel. The hydrogel forming polymer includes a water-soluble polymer and an adhesion promotor chemically and/or physically conjugated to the water-soluble polymer. The embodiments also provide methods of forming a hydrogel forming polymer and use of hydrogel forming polymer to prepare such dental composition.

Abstract: Described herein are dental treatment compositions, more particularly, a dental varnish composition useful in effective fluoridation, enhancement of remineralization the tooth enamel, and hypersensitivity through occlusion of dentine tubule. The dental varnish composition includes a hydrogel system and at least one fluoride source, wherein the dental varnish is water soluble. The hydrogel system includes at least one polyphenol having at least one phenol group, at least one polymer, and a metal ion. Described herein are also methods of making such dental varnish composition.

Abstract: A method for enhancing chondrogenesis in a subject in need thereof comprises administering to the subject an effective amount of a pharmaceutical composition comprising a growth factor bound to hyaluronic acid (HA)-based hydrogel particles (HGPs). The hyaluronic acid (HA)-based hydrogel particles (HGPs) are conjugated with a heparan sulfate proteoglycan (HSPG). Related medicaments and methods for preparing the medicaments are provided.

Abstract: Systems and methods are provided for facilitating mobile commerce interactions between a customer and a merchant, whereby a customer, having initiated a mobile commerce transaction via a mobile device, arrives at a merchant location to complete the transaction. In some embodiments, an intermediate remote server is employed to facilitate communication between a third party app running on a customer mobile computing device, and an app-agnostic merchant computing device residing at a merchant location. In some embodiments, the relative signal strength of a local wireless transceiver associated with a customer mobile computing device is employed to determine the proximity of a customer relative to a merchant at a merchant's premises. This proximity information may be employed to display, on the merchant computing device, a list of customers that is prioritized according to relative proximity.

Abstract: A method for enhancing chondrogenesis in a subject in need thereof comprises administering to the subject an effective amount of a pharmaceutical composition comprising a growth factor bound to hyaluronic acid (HA)-based hydrogel particles (HGPs). The hyaluronic acid (HA)-based hydrogel particles (HGPs) are conjugated with a heparan sulfate proteoglycan (HSPG). Related medicaments and methods for preparing the medicaments are provided.